Spots Global Cancer Trial Database for Study of DNA Samples From Patients With Multiple Myeloma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of DNA Samples From Patients With Multiple Myeloma

Official Title: Proposal for Combining ECOG Myeloma Trial SNP Data

Study ID: NCT00898040

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

polymorphism analysis

Study Description

Brief Summary: RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at DNA samples from patients with multiple myeloma.

Detailed Description: OBJECTIVES: * Determine whether there is an increased frequency of 1 or more polymorphic alleles that are associated with clinical endpoints using custom myeloma single nucleotide polymorphism (SNP) chip analysis of banked DNA samples from patients with multiple myeloma. * Determine SNPs associated with toxicities caused, not by variations in tumor cell genetics, but by individual genetic variations affecting drug activation, distribution, metabolism, and export (ADME). * Determine SNPs associated with response, influenced by the same ADME. * Determine SNPs associated with bone disease (as a variable) among patients with multiple myeloma. * Determine SNPs associated with epidemiology (i.e., risk factors for the development of multiple myeloma). OUTLINE: This is a retrospective, multicenter study. Banked DNA samples are analyzed using a custom single nucleotide polymorphism (SNP) chip to assess approximately 3,590 SNPs from 1,061 genes that are associated with myeloma growth and response. PROJECTED ACCRUAL: A total of 600 patients will be accrued for this study.